U.S. Machinery Stock News

DENTSPLY SIRONA recently announced it has completed its review of strategic alternatives for Wellspect Healthcare, ultimately deciding to retain the subsidiary within its portfolio after considering a potential sale and engaging with multiple interested parties. This outcome highlights the company's belief that Wellspect offers greater value as part of its ongoing operations, underscoring management's renewed focus on driving long-term shareholder benefits through internal business...

Earlier this month, Palo Alto Networks introduced Prisma SASE 4.0, an AI-driven secure access service edge platform with innovations such as real-time browser-based threat neutralization and adaptive private application security. This launch highlights the company's rapid response to the growing importance of enterprise browser security as critical data and applications increasingly shift online, setting them apart in the competitive cybersecurity landscape. We’ll explore how these new AI...

If you’re following Equitable Holdings (NYSE:EQH), this week’s cash tender offer developments are well worth a closer look. The company confirmed the early results and pricing for its purchase of outstanding 4.35% senior notes due 2028, moving decisively to accept a significant portion at the top priority level while leaving tenders at other levels untouched. For equity investors, these proactive moves to optimize the balance sheet can alter the risk landscape and send important signals about...

Earlier this month, Ionis Pharmaceuticals filed a patent infringement lawsuit against Arrowhead Pharmaceuticals in California alleging infringement related to Arrowhead’s investigational drug plozasiran, while Arrowhead had already filed its own lawsuit seeking to invalidate the patent in Delaware. This simultaneous legal action introduces a layer of uncertainty regarding the commercial prospects of Arrowhead’s plozasiran, a potential treatment for familial chylomicronemia syndrome. The dual...

UL Solutions Inc. participated in two major industry events earlier this month, presenting at the Jefferies Mining and Industrials Conference in New York on September 3, 2025, and at the Goldman Sachs Communacopia + Technology Conference in San Francisco on September 10, 2025. These appearances coincided with increased expectations for Federal Reserve interest rate cuts driven by easing inflation data, which has influenced broader market sentiment for companies in technical consulting and...

In recent days, Innovative Industrial Properties (IIPR) saw analysts raise their consensus earnings estimate by 3.02%, even as the company is expected to report a 24.44% decline in quarterly EPS and a 16.6% drop in revenue compared to a year ago. This adjustment in analyst outlook signals growing optimism that contrasts with the widely anticipated earnings and revenue declines facing the company. We'll explore how renewed analyst optimism, despite projected financial headwinds, could...

In September 2025, UniFirst First Aid + Safety and Soundtrace announced a partnership to provide on-site, AI-powered audiometric testing services to help U.S. employers comply with OSHA hearing conservation standards and protect workers from hearing loss. This collaboration directly addresses long-standing compliance and safety challenges faced by businesses exposed to hazardous noise, offering improved efficiency and proactive risk management for workforce health. We'll explore how this new...

Gates Ventures, LLC, a significant shareholder, recently sold 1,470,700 shares of Evolv Technologies Holdings after the company reported a 29% year-over-year revenue increase in Q2 driven by new customer wins and expanded deployments. Alongside strong earnings, Evolv Technologies Holdings resolved important legal matters and secured key contracts, leading analysts to express greater confidence in its strategic direction and growth opportunities. We'll explore how the successful resolution of...

Summit Therapeutics announced new Phase III HARMONi trial data at WCLC 2025, revealing that ivonescimab in combination with chemotherapy delivered clinically meaningful efficacy and a manageable safety profile in patients with EGFR-mutated non-small cell lung cancer who had progressed following 3rd generation EGFR-TKI treatment. This is the first instance where a treatment in this patient population showed positive trends in both overall survival and progression-free survival, an area where...

If you have been watching Frontier Communications Parent stock and wondering what to do next, you are not alone. Plenty of investors are trying to figure out where this story leads, especially after a year marked by both steady gains and a few surprises. Frontier's share price closed at $37.53 most recently, up 0.7% over the last week and 1.1% in the past month. For those looking back a bit further, the momentum is clearer: shares have jumped 7.8% year to date, and if you stretch the timeline...

GE HealthCare announced in early September a distribution and services agreement with CardioNavix to expand access to Flyrcado™, its new cardiac PET imaging agent, to hospitals and outpatient practices across the U.S. This collaboration is positioned to increase adoption of advanced cardiac imaging in office-based care settings, highlighted by Flyrcado's higher diagnostic efficacy over traditional methods. We'll now examine what this expanded access to Flyrcado in outpatient settings could...

Thinking about what to do with Soho House & Co stock at this price? You are not alone. This company’s long-term growth story has been building a lot of buzz, and the past year has given shareholders a taste of just how fast things can change. After holding steady in the past week, Soho House & Co has soared 15.8% over the past month and is up a striking 64.8% in the last year. In fact, since going public, it has delivered a 56.4% gain in just three years. These are impressive numbers by any...

Cable One (CABO) stock has had its share of ups and downs, but recent moves have many investors wondering if now is the time to pay closer attention. If you have been on the fence or watching from the sidelines, it is understandable. Cable One's share price has seen some sharp swings that could signal shifting sentiment, even if there is no single event driving this volatility. For anyone weighing a position, it is worth diving into what is actually going on under the surface. Putting the...

Kaspi.kz (NasdaqGS:KSPI) may not have made the front pages this week, but its recent stock moves are quietly demanding more attention from investors who like to dig deeper. There hasn’t been any headline-grabbing news to explain the shift, leaving some market watchers to wonder if this is just a blip, or a hint that something bigger is brewing below the surface. Sometimes, when things get quiet, it’s worth asking if the market is rethinking what a company is really worth. Looking over the...

ServiceNow recently launched its Zurich platform release, introducing advanced capabilities for multi-agent AI development, enhanced enterprise security, and AI-driven workflow automation across industries. Expanded partnerships, such as the collaboration with Genesys on agentic AI, highlight ServiceNow’s push to unify customer experience and operations through intelligent, interoperable enterprise tools. We’ll explore how these advances in enterprise AI security and cross-platform...

Mobileye Global (MBLY) is making headlines after the European Union moved to partially pause its free trade agreement with Israel in response to ongoing tensions in the region. This matters for investors because Mobileye, an Israel-based innovator supplying advanced driver-assistance systems, counts major European automakers like Volkswagen, BMW, and Stellantis among its key clients. The prospect of new tariffs or changing trade conditions introduces additional risk to Mobileye’s revenue...

Earlier this month, Arcutis Biotherapeutics announced the submission of a supplemental New Drug Application to the FDA seeking to expand ZORYVE cream 0.3% approval for use in treating plaque psoriasis in children as young as two years old, supported by favorable clinical study data. If approved, ZORYVE would become the first and only topical PDE4 inhibitor indicated for this age group, highlighting a potential expansion in the pediatric plaque psoriasis treatment market. We'll examine how...

Marzetti (MZTI) is attracting fresh attention after a recent analysis spotlighted its Return On Capital Employed (ROCE) at 21%, putting it far ahead of the food industry’s 10% average. What is especially interesting is that Marzetti has managed to grow the capital it uses by 26% over the last five years without sacrificing these hefty returns. This signals that management is finding places to redeploy profits for strong growth over the long haul. This kind of performance tends to get...

If you are watching ResMed (RMD) right now, you know there has been a flurry of activity. The company recently unveiled its Global Sleep Institute at the World Sleep Congress, a move aimed at rallying clinicians, researchers, and policymakers to tackle sleep health problems on a global scale. Pair that with the acquisition of VirtuOx, which adds at-home diagnostic muscle, and there is a clear message: ResMed is leaning into innovation and broadening its reach in digital respiratory...

If you have been watching Entegris (ENTG) lately, you might have noticed the stock’s recent ups and downs do not seem to be tied to any dramatic news or game-changing announcements. Sometimes, it is the absence of a clear catalyst that gets investors wondering whether there is something under the surface, or if the market is simply taking a breather. For long-term shareholders and new investors alike, these calm stretches can actually spark the biggest debates about what happens next. Over...

If you have been watching Scholar Rock Holding (SRRK), you know investors are buzzing as the company gears up for a potential U.S. launch of apitegromab, their lead drug candidate. As the first and only muscle-targeted therapy to deliver real, statistically significant functional improvement in spinal muscular atrophy, apitegromab holds promise for a rare but challenging disease. The build-up to a possible regulatory green light and mounting optimism about the drug’s commercial chance is...

If you have been keeping an eye on Youlife Group (NasdaqCM:YOUL) lately, it is hard to miss the excitement building around its stock. After announcing standout earnings for the first half of 2025, including a sizeable jump in both revenue and profit, Youlife also sealed the deal on a joint venture with Beijing Galbot Co., Ltd. This move, together with plans to expand its reach across HR, AI, and vocational training, has investors buzzing about what could come next for the company. The impact...

In recent months, several insiders at LeMaitre Vascular, including Chairman & CEO George LeMaitre, sold significant amounts of company stock, with no insider purchases on record and total insider ownership now at 7.9%. This pattern of ongoing insider selling, particularly involving the CEO's US$8.2 million transaction, raises questions among investors about leadership’s confidence in the company’s current valuation. Given the recent series of insider stock sales, we'll explore how this...

Nvidia (NVDA) has been on the minds of many investors lately, even without a major triggering event driving headlines. Whenever a stock as widely followed as Nvidia sees active trading or nudges in price, it naturally prompts the classic questions: are we witnessing an early signal of something bigger under the surface, or is this simply part of the regular ebb and flow of a market leader? Looking at the bigger picture, Nvidia remains firmly in the spotlight. The company’s stock climbed...